[ Inglés] What Is High-Risk CLL?

Published on

Topics include: Treatments and Understanding

What characteristics of chronic lymphocytic leukemia (CLL) are considered high-risk? Will traditional treatment methods still work? CLL expert Dr. Jeff Sharman from The US Oncology Network describes what disease features will distinguish a high-risk condition and the latest technology available for a CLL treatment strategy. Watch now to learn more.

Provided by CLL Global Research Foundation, which received support from AbbVie Inc., Gilead Sciences, TG Therapeutics, Pharmacyclics LLC and Janssen Biotech, Inc., and Genentech. Produced by Patient Power in collaboration with The US Oncology Network, Compass Oncology, and Willamette Valley Cancer Institute and Research Center.

View more programs featuring and

Produced in association with , , and

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

Dr. Sharman, what is high-risk CLL, and are there advances for it?

Dr. Sharman:   

I think a lot of the advances are really even more dramatic amongst patients with high-risk CLL. What is high-risk CLL? There's, I wouldn’t say that there's one uniform definition of high-risk CLL for every circumstance, but there are certain things we put into that bucket. Patients with 17P deletion or P53 mutations, that is concerns us that our traditional chemo-immunotherapy approaches aren’t going to be particularly good. They don’t last very long. Short remissions. Patients who relapse very early after a prior chemo-immunotherapy regimen, also a potential high-risk group.

I think now as the field is shifting more towards these targeted agents. We are looking at looking at 17P and its impact on patients treated with ibrutinib (Imbruvica), and it does look like patients with 17P may not get as good a benefit as the patients without 17P. However, they still do better on ibrutinib than anything previously. I think that this is a shifting field right now and what was high-risk just a short while ago may be different than what’s high-risk in the near term. 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Strategies for Dealing With CLL Treatment Resistance

Inhibitors and targeted therapies have changed the landscape of CLL treatment, so what can patients expect from modern medicine? Dr. Jeff Sharman talks about their design, capability and potential for drug resistance while using them.

Published:

How to Detect, Identify and Treat Subtypes of CLL

Every patient’s CLL is different, so how do doctors tell which CLL treatment is right? Dr. Kathryn Kolibaba and Dr. Stephen Spurgeon discuss.

Published:

ROR1: An Update From ASH 2017

What have researchers discovered about ROR1 and its role in targeted CLL therapies? Watch now and find out about new approved treatments from our on-site ASH 2017 coverage.

Published:

Advertisement
Únete a Nuestra Comunidad Regístrate para Eventos Lee Nuestro Último Post
Advertisement

Page last updated on June 14, 2019